Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches - PowerPoint PPT Presentation

Loading...

PPT – Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches PowerPoint presentation | free to download - id: 7ea887-ODc0N



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches

Description:

This report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC). – PowerPoint PPT presentation

Number of Views:7

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches


1
Ovarian Cancer Therapeutics in Asia-Pacific
Markets to 2020 - Off-patent Chemo-regimens to
Retain Dominance Despite New Launches
Single User License - 4995 Site User
License - 9990 Corporate User License -
14985 Publication Date - Jan 2015 Pages -
126 To know more details, email to
debora_at_reportstack.com
2
Summary
  • This report provides estimates of the market size
    for 2013, along with forecasts until 2020 for the
    Asia-Pacific markets of India, China, Australia
    and Japan. It also covers disease epidemiology,
    treatment algorithms, treatment patterns,
    in-depth analysis of clinical trials including
    failure rates and pipeline analysis, and analysis
    of deals relevant to Ovarian Cancer (OC).
  • Platinum-based chemotherapy, predominantly the
    chemotherapy regimen paclitaxel and carboplatin,
    is the standard of care for the treatment of
    platinum-sensitive OC (both first-line and
    recurrent). The initial treatment is quite
    effective, with the majority of patients entering
    remission. However, almost all relapse, and after
    successive periods of remission and relapse
    either die or progress to platinum-resistant
    disease, for which the prognosis is poor.

3
Scope
  • A brief introduction to OC, including the
    diseases pathogenesis, risk factors and
    diagnosis
  • In-depth analysis of the drug combinations used
    in the treatment of OC, including analyses of
    their safety, efficacy, and place in the disease
    treatment algorithm, as well as a heat map
    comparing the drug combinations in terms of
    safety and efficacy
  • A comprehensive review of the pipeline for OC
    therapies, including individual analysis of a
    number of late-stage pipeline drugs that have the
    potential to enter the market in the forecast
    period the pipeline is analyzed on the basis of
    phase distribution, molecule type and molecular
    target, and route of administration
  • Discussion of the drivers and barriers for market
    growth

4
Key Benefits
  • Understand the efficacy and safety of the current
    monotherapies and drug combinations used in the
    treatment of OC, with in-depth analysis of the
    disease treatment algorithm
  • Understand the key signaling pathways and
    molecular targets currently under investigation
    in OC drug development
  • Understand the vast scope of the pipeline,
    including which molecule types and mechanisms of
    action are prominent
  • Observe the trends in clinical trial duration and
    size among clinical phases and molecule types,
    and use the clinical trial failure rate analysis
    to assess the risk profiles of current and/or
    future developmental programs for OC therapeutics
  • Assess the potential clinical and commercial
    impact of current late-stage pipeline molecules
    in the OC therapeutics market

5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com
About PowerShow.com